Gene Biotherapeutics Inc - ESG Rating & Company Profile powered by AI
Check the end of the page for potential risks for Gene Biotherapeutics Inc based on industry, location and size. This analysis of Gene Biotherapeutics Inc incorporates data from across the internet and also from public filings by Gene Biotherapeutics Inc. This ESG score for Gene Biotherapeutics Inc represents the company's reporting of the UN Sustainable Development Goals.
Gene Biotherapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | Gene Biotherapeutics Inc | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Gene Biotherapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Gene Biotherapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Gene Biotherapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Gene Biotherapeutics Inc offer flexible work?
Sign up for free to unlockDoes Gene Biotherapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Gene Biotherapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Gene Biotherapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Gene Biotherapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Gene Biotherapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Gene Biotherapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Gene Biotherapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Gene Biotherapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Gene Biotherapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Gene Biotherapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Gene Biotherapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Gene Biotherapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Gene Biotherapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Gene Biotherapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies to manufacture the Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.